Tech Company Financing Transactions
Draig Therapeutics Funding Round
Access Biotechnology, Canaan Partners and ICG Ventures invested in a $140 million Series A venture round for Draig Therapeutics. The round was announced on 6/18/2025.
Transaction Overview
Company Name
Announced On
6/18/2025
Transaction Type
Venture Equity
Amount
$140,000,000
Round
Series A
Investors
Access Biotechnology (Lead Investor) (Liam Ratcliffe)
Proceeds Purpose
The new funds will enable Draig to advance its lead candidate DT-101, a next-generation AMPA receptor positive allosteric modulator (PAM), into Phase 2 trials for Major Depressive Disorder in 2025.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Sbarc | Spark, Maindy Rd
Cardiff, CF24 4HQ
UK
Cardiff, CF24 4HQ
UK
Phone
Undisclosed
Website
Email Address
Overview
Draig Therapeutics is a clinical-stage company with a mission to transform treatments in Neuropsychiatry. The company is leveraging its founders' unique scientific expertise in modulating the core glutamate / GABA pathways that play a critical role in neuropsychiatric diseases to advance a pipeline of groundbreaking therapies designed to address large unmet patient needs, including in Major Depressive Disorder (MDD).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Ruth McKernan
Browse more venture capital transactions:
Prev: 6/18/2025: BitVault venture capital transaction
Next: 6/18/2025: Materna Medical venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records on this site come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs